COMPANY PROFILE / #1437
Greenstone Biosciences
Palo Alto, CAVenture Capital-Backed
OVERVIEW
Operator of a drug discovery platform intended to accelerate the development of effective therapies for patients. The company's platform uses artificial intelligence or machine learning computing and human-induced pluripotent cells technology to transform drug discovery from a slow, sequential and high-failure process into a rapid, integrated and novel computational platform, enabling patients with safe and effective therapeutics for diseases with urgent unmet needs.
已融资20.20
最新估值123.00
员工数19
成立年份2021
公司概况
- Companies
- Greenstone Biosciences
- Description
- Operator of a drug discovery platform intended to accelerate the development of effective therapies for patients. The company's platform uses artificial intelligence or machine learning computing and human-induced pluripotent cells technology to transform drug discovery from a slow, sequential and high-failure process into a rapid, integrated and novel computational platform, enabling patients with safe and effective therapeutics for diseases with urgent unmet needs.
- Website
- www.greenstonebio.com
- HQ Location
- Palo Alto, CA
- Year Founded
- 2021
- Keywords
- computational biology company, drug discovery, drug discovery company, drug discovery platform, machine learning ai, stem cell biology
- Competitors
- —
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 20.20
- First Financing Date
- 04-May-2022
- First Financing Size
- 10.20
- First Financing Valuation
- 60.00
- Last Financing Date
- 08-May-2025
- Last Financing Deal Type
- Early Stage VC
- Last Financing Size
- 10.00
- Last Financing Valuation
- 123.00
- Last Financing Status
- Completed
- Last Known Valuation
- 123.00
- Last Known Valuation Date
- 08-May-2025
- Last Known Valuation Deal Type
- Early Stage VC
- Valuation Estimate
- 241.98
- Valuation Estimate Growth Rate
- 96.73%
- Active Investors
- A&E Investments, Aramco Ventures, California Institute for Regenerative Medicine, National Institutes of Health, Walden Catalyst
- # Active Investors
- 5
- Acquirers
- —
团队与联系人
- Employees
- 19
- Employee Growth %
- 46.15%
- Employee History
- 2025: 19, 2024: 13, 2023: 13
- Primary Contact
- Amit Parikh
- Primary Contact Title
- Chief Financial Officer
- Primary Contact Email
- aparikh@greenstonebio.com
- Primary Contact Phone
- +1 (650) 714-7060
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- —
- Size Multiple
- —
- Size Multiple % Change
- —
- Size Multiple Change
- —
- Size Multiple Percentile
- —
- Majestic Referring Domains
- —
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- —
- Success Probability Over Time – 3 Year
- —
- Success Probability Over Time – 5 Year
- —
记录来源：public.companies · 原始序号 #1437 · 所有字段均按数据库原值展示。